Huilian Bu

Huilian Bu

Auto-generated profile, based on publicly available information

Huilian Bu

Department of Pain Management The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 October 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
HGHai-Ming Guo
Hai-Ming Guo
YZYu Zhang
Yu Zhang
YZYan Zhang
Yan Zhang
PJPeng-Fei Jiao
Peng-Fei Jiao
XFXiao-Chong Fan
Xiao-Chong Fan
HBHui-Lian Bu
Hui-Lian Bu

1 October 2022 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
HBHuilian Bu
Huilian Bu
PJPengfei Jiao
Pengfei Jiao
XFXiaochong Fan
Xiaochong Fan
YGYan Gao
Yan Gao
LZLirong Zhang
Lirong Zhang
HGHaiming Guo
Haiming Guo
Huilian Bu, Pengfei Jiao, Xiaochong Fan, Yan Gao, Lirong Zhang, and Haiming Guo. Korean J Pain 2022;35:391-402. https://doi.org/10.3344/kjp.2022.35.4.391

8 December 2023 in Journal of Neurochemistry
Verified
Journal Article
Closed access
XXXuyang Xiao
Xuyang Xiao
JYJingjie Yang
Jingjie Yang
QBQian Bai
Qian Bai
ZWZhitao Wang
Zhitao Wang
YCYan Chen
Yan Chen
HBHuilian Bu
Huilian Bu

1 January 2026 in Brazilian Journal of Case Reports
Verified
Journal Article
Open access
HBHuilian Bu
Huilian Bu
PJPengfei Jiao
Pengfei Jiao
YWYanping Wang
Yanping Wang
XLXinxin Li
Xinxin Li
CHChen Huang
Chen Huang
XFXiaochong Fan
Xiaochong Fan
Coronavirus disease 2019 (COVID-19) may trigger peripheral nerve injury accompanied by intractable neuropathic pain and limb muscular weakness, which frequently fails standard pharmacotherapy and rehabilitation. Spinal cord stimulation (SCS) is an established neuromodulation modality for neuropathic pain management and peripheral nerve functional repair, yet clinical evidence supporting SCS for COVID-19-associated multiple peripheral neuropathy remains scarce, especially in patients with mild COVID-19 lacking mechanical nerve compression risk factors. A 37-year-old male developed refractory bilateral-distributed left-limb neuropathic pain (VAS:6–9) and left-hand weakness following familial clustered mild COVID-19 infection without prone ventilation or external nerve compression. Electroneurography/electromyography (ENG/EMG) confirmed incomplete demyelinating injury involving left brachial plexus, peroneal nerve and tibial nerve; brachial plexus MRI demonstrated local neural edema with indistinct perineural architecture. Conventional pharmacotherapy, physical rehabilitation and paravertebral nerve block only achieved marginal pain improvement. Combined short-term epidural SCS targeting cervical C5–C7 and thoracic T9–T11 was implanted for a total of 14 days. At discharge, VAS decreased to 3 for left hand and 6 for left foot with partial improvement in hand muscle strength. At 1-month and 3-month outpatient follow-up, pain was well-controlled at VAS=2, left-hand muscle strength recovered substantially, and all prescribed analgesics were completely tapered and discontinued. Short-term combined cervicolumbar SCS represents a safe optional neuromodulation alternative for refractory COVID-19-induced multiple peripheral demyelinating neuropathy unresponsive to routine treatment. This intervention effectively alleviates intractable neuropathic pain, facilitates limb muscle functional recovery and reduces long-term reliance on analgesics. Early SCS trial can be considered as individualized salvage therapy for refractory long-COVID peripheral neurological sequelae.